Cabozantinib: An evolving therapy for hepatocellular carcinoma

Clicks: 187
ID: 267326
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Hepatocellular carcinoma (HCC) is rising in incidence and remains a leading cause of cancer-related death. After a decade of disappointing trials following the approval of sorafenib for patients with advanced HCC, a number of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies targeting angi …
Reference Key
ab2021cancercabozantinib: Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors El-Khoueiry AB;Hanna DL;Llovet J;Kelley RK;;
Journal Cancer treatment reviews
Year 2021
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/34029957
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review animals humans pubmed abstract nih national institutes of health national library of medicine carcinoma hepatocellular / pathology liver neoplasms / pathology liver neoplasms / drug therapy* hepatocellular / drug therapy* pmid:34029957 doi:10.1016/j.ctrv.2021.102221 anthony b el-khoueiry diana l hanna robin kate kelley anilides / therapeutic use* antineoplastic agents / therapeutic use* pyridines / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.